{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T04:13:21Z","timestamp":1773634401700,"version":"3.50.1"},"reference-count":50,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.2217\/fmb.10.20","type":"journal-article","created":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T13:38:33Z","timestamp":1269956313000},"page":"539-548","source":"Crossref","is-referenced-by-count":17,"title":["Fidaxomicin: A New Macrocyclic, RNA Polymerase-Inhibiting Antibiotic for the Treatment of\n            <i>Clostridium Difficile<\/i>\n            Infections"],"prefix":"10.1080","volume":"5","author":[{"given":"Ian R","family":"Poxton","sequence":"first","affiliation":[{"name":"Centre for Infectious Diseases, University of Edinburgh College of Medicine &amp; Veterinary Medicine, The Chancellor\u2018s Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK.Tel.:  Fax:"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2010,3,30]]},"reference":[{"key":"e_1_3_3_3_1_1","doi-asserted-by":"publisher","DOI":"10.1086\/521865"},{"key":"e_1_3_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-10-200611210-00008"},{"key":"e_1_3_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2009.08.016"},{"key":"e_1_3_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051639"},{"key":"e_1_3_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1086\/502539"},{"key":"e_1_3_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.02.073"},{"key":"e_1_3_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.2807\/esm.12.06.00714-en"},{"key":"e_1_3_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.2807\/ese.13.31.18942-en"},{"key":"e_1_3_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2003.00683.x"},{"key":"e_1_3_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01824.x"},{"key":"e_1_3_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.2807\/ese.14.14.19169-en"},{"key":"e_1_3_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03141.x"},{"key":"e_1_3_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1406.071447"},{"key":"e_1_3_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1086\/596703"},{"key":"e_1_3_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.2807\/ese.13.31.18943-en"},{"key":"e_1_3_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.1554"},{"key":"e_1_3_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(09)70014-7"},{"key":"e_1_3_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2009.03099.x"},{"key":"e_1_3_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1086\/596552"},{"key":"e_1_3_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e32833229ce"},{"key":"e_1_3_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1086\/592710"},{"key":"e_1_3_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39231.599815.55"},{"key":"e_1_3_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.050350"},{"key":"e_1_3_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2009.08.005"},{"key":"e_1_3_3_3_25_1","first-page":"CD004611","article-title":"Probiotics for treatment of Clostridium difficile-associated colitis in adults.","author":"Pillai A","year":"2008","unstructured":"Pillai A , NelsonR: Probiotics for treatment of Clostridium difficile-associated colitis in adults.Cochrane Database Syst. Rev.CD004611 (2008).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcp118"},{"key":"e_1_3_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.2807\/ese.14.34.19316-en"},{"key":"e_1_3_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(09)70017-2"},{"key":"e_1_3_3_3_29_1","unstructured":"Bouza E DrydenM MohammedR et al.: Results of a Phase III trial comparing tolevamer vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhoea. Presented at: 18th European Congress of Clinical Microbiology and Infectious Disease. Barcelona Spain 19\u201322 April 2008 (Abstract O464)."},{"key":"e_1_3_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.12.4898-4902.2004"},{"key":"e_1_3_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.11.4430-4434.2004"},{"key":"e_1_3_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01443-07"},{"key":"e_1_3_3_3_33_1","first-page":"168","article-title":"Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic.","volume":"8","author":"Johnson AP","year":"2007","unstructured":"Johnson AP : Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic.Curr. Opin. Investig. Drugs8 , 168\u2013173 (2007).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"e_1_3_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01045-07"},{"key":"e_1_3_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01442-07"},{"key":"e_1_3_3_3_36_1","unstructured":"Miller MA MullaneKM WeissK et al.: Faster time to resolution of diarrhea with fidaxomicin vs. vancomycin in patients with Clostridium difficile infection (CDI). Presented at: 47th IDSA Annual Meeting. Philadelphia PA USA 29 October\u20131 November 2009."},{"key":"e_1_3_3_3_37_1","unstructured":"Golan Y MullaneKM MillerMA et al.: Low recurrence rate among patients with C. difficile infection treated with fidaxomicin. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco CA USA 12\u201315 September 2009."},{"key":"e_1_3_3_3_38_1","unstructured":"Sears P LouieTJ MullaneKM MillerMA ShueYK: Pharmacokinetics\/pharmacodynamics (PK\/PD) of fidaxomicin in treatment of Clostridium difficile infection (CDI). Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco CA USA 12\u201315 September 2009."},{"key":"e_1_3_3_3_39_1","unstructured":"Gorbach S WeissK SearsP PullmanJ: Safety of fidaxomicin versus vancomycin in treatment of Clostridium difficile infection. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco CA USA 12\u201315 September 2009."},{"key":"e_1_3_3_3_40_1","unstructured":"Miller MA MullaneKM WeissK et al.: Age serum albumin and leukocytosis\/fever predict clinical outcomes of Clostridium difficile infection treated with fidaxomicin and vancomycin. Presented at: 47th IDSA Annual Meeting. Philadelphia PA USA 29 October\u20131 November 2009."},{"key":"e_1_3_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2009.09.005"},{"key":"e_1_3_3_3_42_1","unstructured":"Mullane KM MillerMA WeissK et al.: Effect of concomitant antibiotics on treatment of Clostridium difficile infection with fidaxomicin or vancomycin. Presented at: 47th IDSA Annual Meeting. Philadelphia PA USA 29 October\u20131 November 2009."},{"key":"e_1_3_3_3_43_1","unstructured":"Okumu F WalshRB SearsP Shue Y-K: Safety and pharmacokinetics of OPT-80 a novel antibiotic for treatment of Clostridium difficile associated diarrhea (CDAD). Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC USA 30 October\u20132 November 2004."},{"key":"e_1_3_3_3_44_1","unstructured":"Donskey CJ : Acquisition and overgrowth of vancomycin-resistant enterococci in patients treated with either fidaxomicin or vancomycin for C. difficile infection. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco CA USA 12\u201315 September 2009."},{"key":"e_1_3_3_4_2_1","unstructured":"Health Protection Scotland: Annual report on the surveillance of Clostridium difficile-associated disease (CDAD) in Scotland October 2006\u2013September 2007. The HPS C. difficile Working Group December 2007. www.documents.hps.scot.nhs.uk\/hai\/sshaip\/publications\/cdad\/2007\u20132012\u201320-ar-cdad.pdf"},{"key":"e_1_3_3_4_3_1","unstructured":"Health Protection Agency: Surveillance of Healthcare Associated Infections Report: 2008. Health Protection Agency London July 2008. www.hpa.org.uk\/web\/HPAwebFile\/HPAweb_C\/1216193833496"},{"key":"e_1_3_3_4_4_1","unstructured":"KISS Krankenhaus-Infektions-Surveillance-System. Modul CDAD-KISS. (KISS Hospital Infections Surveillance System. Module CDAD-KISS.) National Reference Centre for Surveillance of Nosocomial Infections Berlin 9 September 2008. www.nrz-hygiene.de\/dwnld\/CDAD_Referenzdaten_2007.pdf"},{"key":"e_1_3_3_4_5_1","unstructured":"Health Protection Agency quarterly analyses: mandatory MRSA bacteraemia and Clostridium difficile infections (July 2007\u2013September 2009). www.hpa.org.uk\/web\/HPAwebFile\/HPAweb_C\/1259152023516"},{"key":"e_1_3_3_4_6_1","unstructured":"Optimer: fidaxomicin (OPT-80). www.optimerpharma.com\/resources.asp?dept=7"},{"key":"e_1_3_3_4_7_1","unstructured":"Optimer. www.optimerpharma.com"}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fmb.10.20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:39:09Z","timestamp":1719124749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fmb.10.20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,30]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.2217\/fmb.10.20"],"URL":"https:\/\/doi.org\/10.2217\/fmb.10.20","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,30]]}}}